ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating the Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03391466
Recruitment Status : Recruiting
First Posted : January 5, 2018
Last Update Posted : May 21, 2018
Sponsor:
Information provided by (Responsible Party):
Kite, A Gilead Company

Brief Summary:
The purpose of this study is to evaluate whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in patients with relapsed/refractory DLBCL.

Condition or disease Intervention/treatment Phase
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Drug: Axicabtagene Ciloleucel Drug: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders. Phase 3

Detailed Description:

This is a phase 3 randomized, open-label, multicenter study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in subjects with relapsed/refractory DLBCL. Adult subjects with relapsed/refractory DLBCL after first-line rituximab and anthracycline-based chemotherapy will be randomized in a 1:1 ratio to receive axicabtagene ciloleucel or standard of care second-line therapy.

Standard of care will consist of a protocol-defined, platinum-based salvage combination chemotherapy regimen followed by high-dose therapy and autologous stem cell transplant in those who respond to salvage chemotherapy.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 350 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Two arms, SOC and experimental treatment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Open-Label Study Evaluating Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Actual Study Start Date : December 14, 2017
Estimated Primary Completion Date : January 15, 2022
Estimated Study Completion Date : January 15, 2035


Arm Intervention/treatment
Experimental: Axicabtagene Ciloleucel Treatment Drug: Axicabtagene Ciloleucel
Intervention Description: N/A.
Other Names:
  • KTE-C19
  • axi-cel
Active Comparator: Standard of Care Therapy Drug: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.
Intervention Description: N/A.



Primary Outcome Measures :
  1. Event Free Survival [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Objective Response Rate [ Time Frame: 3 years ]
  2. Overall Survival [ Time Frame: 4 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Histologically proven DLBCL, including transformation from follicular lymphoma
  2. Relapsed or refractory disease after first-line chemoimmunotherapy

    • Refractory disease is defined as no complete remission to first-line therapy; subjects who are intolerant to first-line therapy are excluded.

      • Progressive disease (PD) as best response to first-line therapy
      • Stable disease (SD) as best response after at least 4 cycles of first-line therapy
      • Partial response (PR) as best response after at least 6 cycles and biopsy-proven residual disease or disease progression ≤ 12 months from initiation of therapy
    • Relapsed disease defined as complete remission to first-line therapy followed by biopsy-proven relapse ≤ 12 months of initiating first-line therapy
  3. Subjects must have received adequate first-line therapy including at a minimum:

    • Anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20 negative, and
    • An anthracycline containing chemotherapy regimen
  4. No known history or suspicion of central nervous system involvement by lymphoma
  5. ECOG performance status of 0 or 1
  6. Adequate bone marrow function as evidenced by:

    • ANC ≥ 1000/uL
    • Platelet ≥ 75,000/uL
    • Absolute lymphocyte count ≥ 100/uL
  7. Adequate renal, hepatic, cardiac, and pulmonary function as evidenced by:

    • Creatinine clearance (Cockcroft Gault) ≥ 60 mL/min
    • Serum ALT/AST ≤ 2.5 ULN
    • Total bilirubin ≤ 1.5 mg/dl
    • Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion as determined by an ECHO, and no clinically significant ECG findings
    • No clinically significant pleural effusion
    • Baseline oxygen saturation > 92% on room air

Key Exclusion Criteria:

  1. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (eg cervix, bladder, breast) unless disease free for at least 3 years
  2. Received more than one line of therapy for DLBCL
  3. History of autologous or allogeneic stem cell transplant
  4. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous antimicrobials for management.
  5. Known history of infection with human immunodeficiency virus (HIV) or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive). If there is a positive history of treated hepatitis B or hepatitis C, the viral load must be undetectable per quantitative polymerase chain reaction (PCR) and/or nucleic acid testing.
  6. Subjects with detectable cerebrospinal fluid malignant cells or known brain metastases, or with a history of cerebrospinal fluid malignant cells or brain metastases.
  7. History or presence of non-malignant CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement
  8. Presence of any indwelling line or drain. Dedicated central venous access catheter such as a Port-a-Cath or Hickman catheter are permitted.
  9. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, New York Heart Association Class II or greater congestive heart failure, or other clinically significant cardiac diseases within 12 months of enrollment
  10. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment
  11. History of autoimmune disease, requiring systemic immunosuppression and/or systemic disease modifying agents within the last 2 years
  12. History of anti-CD19 or CAR-T therapy or history of prior randomization in ZUMA-7

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03391466


Contacts
Contact: Kite MD +1-844-454-5483 medinfo@kitepharma.com

Locations
United States, Arizona
Banner MD Anderson Cancer Center Recruiting
Gilbert, Arizona, United States, 85234
Contact: Andrea Winkle       andrea.winkle@bannerhealth.com   
Principal Investigator: Javier Munoz, MD         
United States, California
Stanford University Recruiting
Stanford, California, United States, 94305
Contact: Juliana Kristine Craig       jkcraig@stanford.edu   
Principal Investigator: David Miklos, MD         
United States, Florida
Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 12902
Contact: Matthew Scott       Matthew.Scott@moffitt.org   
Principal Investigator: Fred Locke, MD         
United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: Heelai Wardak       hwardak1@medicine.bsd.uchicago.edu   
Principal Investigator: Peter Riedell, MD         
United States, Iowa
University of Iowa Recruiting
Iowa City, Iowa, United States, 52242
Contact: Pamela Zehr       pamela-zehr@uiowa.edu   
Principal Investigator: Umar Farooq, MD         
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Michael Rocchio       MichaelJ_Rocchio@DFCI.HARVARD.EDU   
Principal Investigator: Caron Jacobson, MD         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Michelle Folken       mccstudyintake@mayo.edu   
Principal Investigator: Patrick Johnston, MD         
United States, Missouri
Washington University Recruiting
Saint Louis, Missouri, United States, 63130
Contact: Phil Powell       cpowell@dom.wustl.edu   
Principal Investigator: Armin Ghobadi, MD         
United States, Pennsylvania
University of Pittsburgh Medical Center Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Megan Fritz       fritzm2@upmc.edu   
Principal Investigator: Kathleen Dorritie, MD         
United States, Tennessee
Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Contact: Kristina Salfarlie       kristina.salfarlie@sarahcannon.com   
Principal Investigator: Ian Flinn, MD         
Vanderbilt University Recruiting
Nashville, Tennessee, United States, 37232
Contact: Tom Leonard-Martin       thomas.leonard-martin@Vanderbilt.Edu   
Principal Investigator: Olalekan Oluwole, MD         
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Sherry Atkins       sadkins@mdanderson.org   
Principal Investigator: Jason Westin, MD         
Sponsors and Collaborators
Kite, A Gilead Company

Responsible Party: Kite, A Gilead Company
ClinicalTrials.gov Identifier: NCT03391466     History of Changes
Other Study ID Numbers: KTE-C19-107
First Posted: January 5, 2018    Key Record Dates
Last Update Posted: May 21, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
URL: http://

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin